Biovie Inc. (BIVIW) — Quarterly Report

AI-Powered SEC Filing Analysis

← All BIVIW filings
Latest Quarterly Report Filed: 2026-05-11

Key Insights

  • The filing is dated 2026-05-11 for Q3 fiscal year ending 2026-03-31, indicating BioVie is reporting on a nine-month period (2025-07-01 to 2026-03-31), suggesting potential fiscal year restructuring or extended reporting period.
  • The document structure shows extensive tracking of equity instruments including common stock, warrants, stock options, and RSUs across multiple reporting periods, indicating significant equity-based compensation activity and potential dilution considerations.
  • The presence of a Long COVID Program as a tracked segment suggests this is a material business focus area, with specific financial tracking from 2024-2026, indicating ongoing clinical or commercial development in this therapeutic area.
Filing tone (AI): Neutral
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-11. In the app, any new 10-K, 10-Q or 8-K is analyzed the moment you open it.

Download on theApp Store Get it onGoogle Play
Get it on Google Play Open in app →

Earlier Quarterly Report filings

Filed: 2026-02-06
  • The company reported a significant increase in cash and short-term investments, indicating strong liquidity and the ability to fund ongoing operations.
  • The company has been actively granting stock options and restricted stock units to its employees, suggesting a focus on retaining and incentivizing key talent.
  • The company appears to have made some recent changes to its warrant agreements, which may impact the dilution of existing shareholders.
Filing tone (AI): Positive
View Original Filing →

Other reports for Biovie Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.